Description: PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Home Page: www.puretechhealth.com
6 Tide Street
Boston,
MA
02210
United States
Phone:
617 482 2333
Officers
| Name | Title |
|---|---|
| Dr. Bharatt M. Chowrira J.D., Ph.D. | CEO & Executive Director |
| Ms. Daphne Zohar | Founder, Senior Advisor & Board Observer |
| Dr. Robert S. Langer Jr., Ph.D., ScD | Co-Founder & Non-Executive Director |
| Dr. Eric Elenko Ph.D. | Co-Founder & President |
| Dr. David R. Elmaleh Ph.D. | Co-Founder & Senior Advisor |
| Ms. Lauren A. White M.B.A. | Chief Financial Officer |
| Mr. Eric Green M.B.A. | Chief Operating Officer |
| Ms. Allison Mead Talbot | Head of Communications & Investor Relations |
| Mr. Charles Sherwood III, J.D., Ph.D. | General Counsel & Company Secretary |
| Mr. Spencer Ball | Senior Vice President of Human Resources |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Energy |
|---|---|
| GIC Group: | Energy |
| GIC Industry: | Oil, Gas & Consumable Fuels |
| GIC Sub-Industry: | Coal & Consumable Fuels |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 90 |